The Senate's push to vote on health care is an unprecedentedly opaque process to overhaul a $3 trillion industry, Vox reports. » Read More
By: Jacob Pramuk
Paul's support removes one possible hurdle for Republican leadership in what could prove to be a tight vote. » Read More
By: Jacob Pramuk
It is unclear if Republican Party divisions will again stall the effort to repeal Obamacare. » Read More
Trump promised great things on health care — but endorsed policies that did not deliver, Vox reports.
A vaccine intended to control meningitis could hold the answers to protecting the population from the gonorrhea superbug.
Collaborative relationships with hospitals across the globe are improving patient outcomes and operational efficiencies.
Susan Collins, representing a pivotal vote for the GOP, has not been contacted by Trump ahead of the upcoming health-care vote.
Sen. John McCain's office said Monday evening that he would return to the U.S. Senate on Tuesday.
Alphabet's Verily is betting big on this cancer diagnostics start-up.
Prosecutors could conclude their case as early as Tuesday, and it is not clear if Shkreli's lawyers will present any witnesses.
Donald Trump ramped up the pressure on Senate Republicans as they scramble to move forward with a plan to repeal the Affordable Care Act this week.
Molina Healthcare plans to cut about 1,400 jobs in the next few months, according to an internal company memo.
Strategist David Rosenberg named demographics the single most important factor for investors to monitor over the next decade.
The GOP health bill effort needs new leadership in the Senate and smarter help from President Trump, says Jake Novak.
Trump speaks as Senate Republicans scramble to win the support needed to pass a health-care bill.
President Donald Trump pressured Republicans Monday to approve the Senate's health care bill.
This health investor gets asked all the time what Amazon is doing. Here's what he thinks.
All of Senate majority Leader Mitch McConnell's health-care plans seem to lack support of 50 Republicans, Vox reports.
Merk and Samsung Bioepis have begun selling a less expensive alternative version of rheumatoid arthritis drug Remicade in the United States.
Get the best of CNBC in your inbox